CPT code 0171U designates a Proprietary Laboratory Analyses (PLA) test — the MyMRD® NGS Panel from the Laboratory for Personalized Molecular Medicine — that uses blood or bone marrow to identify minimal residual disease (MRD) by sequencing mutation hotspots across 23 genes implicated in myeloid malignancies such as acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and myelodysplastic syndromes (MDS). As a PLA code, 0171U applies to a single manufacturer’s/test developer’s unique assay and signals the growing role of high-sensitivity NGS MRD testing in hematologic oncology.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context on clinical application of NGS-based MRD detection, the PLA code’s significance for lab billing and payer interactions, and an outline of topics typically addressed in coverage and reimbursement reviews. The publication summarizes benchmarks for utilization and coverage patterns where available, highlights policy and coding considerations specific to PLA-designated assays, and explains clinical scenarios where MRD testing influences disease monitoring and treatment planning.

Data not available in the input for certain fields such as associated taxonomies, specific ICD-10 diagnoses, and related billing codes is noted where applicable elsewhere in the publication.